Technical Analysis for IBIO - iBio, Inc.

Grade Last Price % Change Price Change
grade F 0.6305 -1.82% -0.01
IBIO closed down 1.82 percent on Friday, September 13, 2019, on 8 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Flat
See historical IBIO trend table...

Date Alert Name Type % Chg
1,2,3 Pullback Bullish Bullish Swing Setup 0.00%
Narrow Range Bar Range Contraction 0.00%
NR7 Range Contraction 0.00%
Inside Day Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Oversold Stochastic Weakness 0.00%
1,2,3 Pullback Bullish Bullish Swing Setup -1.82%
Wide Bands Range Expansion -1.82%
Up 3 Days in a Row Strength -1.82%
Up 4 Days in a Row Strength -1.82%

Older signals for IBIO ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
iBio, Inc., a biotechnology company, engages in the development and commercialization of vaccines and therapeutic proteins through its proprietary iBioLaunch platform technology in the United States. Its product portfolio includes seasonal and H1N1 influenza vaccines for the seasonal influenza virus strains; pandemic avian influenza vaccine for the pathogenic avian influenza viruses; and therapeutic vaccines for human papilloma virus. The company also offers biodefense products, including oral anthrax booster vaccine candidates and candidate plague vaccines. In addition, it provides therapeutic protein product candidates comprising human alpha-galactosidase A for the treatment of Fabry disease; human C-1 esterase inhibitor for the treatment of hereditary angioedema; and human alpha-1 antitrypsin for treatment of disorders caused by a deficiency of alpha-1 antitrypsin. Further, the company offers vaccine enhancements through its iBioModulator platform. It has a license and collaboration agreement with Caliber Biotherapeutics, LLC for the development and production of recombinant plant-based biopharmaceuticals. The company is headquartered in Newark, Delaware.
Medicine Biotechnology Disorders Influenza Vaccination Microbiology Vaccines Biopharmaceuticals Hereditary Angioedema Seasonal Influenza Fabry Disease H5n1 Clinical Trials Deficiency Human Papilloma Virus Influenza Vaccines Treatment Of Fabry Disease
Is IBIO a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 3 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 1.4
52 Week Low 0.495
Average Volume 1,119,853
200-Day Moving Average 0.7829
50-Day Moving Average 0.6924
20-Day Moving Average 0.6877
10-Day Moving Average 0.6295
Average True Range 0.0738
ADX 34.27
+DI 28.8644
-DI 16.2411
Chandelier Exit (Long, 3 ATRs ) 1.1786
Chandelier Exit (Short, 3 ATRs ) 0.8014
Upper Bollinger Band 0.8378
Lower Bollinger Band 0.5376
Percent B (%b) 0.31
BandWidth 43.652756
MACD Line -0.0229
MACD Signal Line -0.0186
MACD Histogram -0.0043
Fundamentals Value
Market Cap 58.52 Million
Num Shares 92.8 Million
EPS -0.16
Price-to-Earnings (P/E) Ratio -3.84
Price-to-Sales 74.56
Price-to-Book 3.17
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.68
Resistance 3 (R3) 0.68 0.66 0.67
Resistance 2 (R2) 0.66 0.65 0.66 0.67
Resistance 1 (R1) 0.65 0.64 0.64 0.65 0.66
Pivot Point 0.63 0.63 0.63 0.63 0.63
Support 1 (S1) 0.62 0.62 0.61 0.62 0.60
Support 2 (S2) 0.60 0.61 0.60 0.60
Support 3 (S3) 0.59 0.60 0.59
Support 4 (S4) 0.59